Dallas, Texas 04/11/2014 (FINANCIALSTRENDS) – California’s Gilead Sciences, Inc. (NASDAQ:GILD) has one of the strongest current portfolio as well proven track record towards innovation. The company is also noted to have over 35% has an upside under current financial conditions.
Gilead Sciences, Inc. (NASDAQ:GILD) has in the recent few weeks been seeing an upside. The open-label clinical trials in the Hepatitis C solution by this company – Sovaldi has reported positive results. The company conducted this treatment in open-clinical trials. Sovaldi is often a treatment for patients to respond to DAA as well as direct-acting antivirals. In patients where genotype 1 infections were treated, with Sovaldi in combination with ribavirin, showed 74% cure, in a population which is tough to treat.
Gilead Sciences, Inc.(NASDAQ:GILD) also conducted a second study where the patients who suffered from genotypes 2, which also 3 produced similar results.
Data from these studies were also presented for peer review. Such additional studies for Sovaldi have also been discussed and the treatment option proves that it is the ideal treatment for Hepatitis C. The key factor here is that it can be used regardless of the genotype or disease condition.
Gilead Sciences, Inc. (NASDAQ:GILD) and Sovladi is definitely one of the leading drugs in this category, even as other pharmas such as Enta Pharmaceuticals as well as AbbVie.
It has also to be noted, Bristol-Myers’ also offers a therapy for Genotype 1 patients similar to Sovaldi. The factor, which does not work for Bristol-Myers’ product, is that this therapy takes twice as much longer to treat these genotype 1 patients.
Gilead Sciences, Inc. (NASDAQ:GILD) has already been under tremendous pressures, as a congressional committee is questioning the rationale behind the high-prices of drugs such as Sovaldi. Incidentally, this drug is one of the highest priced in this category of drugs.